Clinical trial

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

NCT00548405

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-10-01

PhasePHASE3

Study timeline

Study start (unknown)2007-10-01Date precision: month

Registry last updated2017-04-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Interventions

Alemtuzumab 12 mgBIOLOGICAL

Alemtuzumab 24 mgBIOLOGICAL

Interferon beta-1aBIOLOGICAL

Sponsors & collaborators

Genzyme, a Sanofi Companylead sponsor

Bayercollaborator

Mapped research locations

Saint PetersburgRussia4 MoscowRussia3 ZagrebCroatia3 BostonMassachusetts, United States2 AtlantaGeorgia, United States2 San AntonioTexas, United States2 SeattleWashington, United States2 TampaFlorida, United States2 BerlinGermany2 MontrealQuebec, Canada2 IndianapolisIndiana, United States2 PhoenixArizona, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00548405 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.